Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Elevation Oncology (ELEV)
NASDAQ:ELEV
Holding ELEV?
Track your performance easily
ELEV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.44 - $5.83
Previous Close$0.61
Volume153.66K
Average Volume (3M)705.27K
Market Cap
$35.54M
Enterprise Value-$36.27M
Total Cash (Recent Filing)$103.07M
Total Debt (Recent Filing)$31.02M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
May 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding59,119,055
10 Day Avg. Volume766,645
30 Day Avg. Volume705,274
Standard Deviation0.74
R-Squared0.00685
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.50
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.86
Forecast
1Y Price Target
$6.50Price Target Upside981.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Elevation Oncology News
PremiumCompany Announcements
Elevation Oncology’s Q3 2024 Highlights and Financial Report
PremiumCompany Announcements
Elevation Oncology Announces Preliminary Phase 1 Trial Results
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Drug DevelopmentElevation continues to enroll patients into the dose expansion portion of the ongoing Phase 1 Study evaluating EO-3021 as a monotherapy to treat advanced unresectable cancers.
Market Potential And Competitive PositioningEO-3021 results from partner CSPC in China in unselected CLDN patients are on par or superior to the FiH data in CLDN-selected patients of two new competitors.
Safety And TolerabilityGiven the favorable reported safety profile, no grade 4 or 5 treatment-emergent adverse events (TEAEs) were reported, which indicates strong potential for EO-3021 as a combination therapy.
Bears Say
Clinical Trial ResultsATG-022 FiH data had the lowest ORR seen to date in this class, which is an important new low anchor for the class.
Comparative EfficacyThe 20% ORR in all-comers represents a significant decline from partner CSPC's reported ORR of 47% in all evaluable patients within its Chinese Ph1 trial.
Stock PerformanceThe stock could face a significant decrease if the ORR is below 30% in upcoming data releases.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ELEV FAQ
What was Elevation Oncology’s price range in the past 12 months?
Elevation Oncology lowest stock price was $0.44 and its highest was $5.83 in the past 12 months.
What is Elevation Oncology’s market cap?
Currently, no data Available
When is Elevation Oncology’s upcoming earnings report date?
Elevation Oncology’s upcoming earnings report date is May 01, 2025 which is in 159 days.
How were Elevation Oncology’s earnings last quarter?
Elevation Oncology released its earnings results on Nov 06, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.19 by -$0.03.
Is Elevation Oncology overvalued?
According to Wall Street analysts Elevation Oncology’s price is currently Undervalued.
Does Elevation Oncology pay dividends?
Elevation Oncology does not currently pay dividends.
What is Elevation Oncology’s EPS estimate?
Elevation Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elevation Oncology have?
Elevation Oncology has 59,119,057 shares outstanding.
What happened to Elevation Oncology’s price movement after its last earnings report?
Elevation Oncology reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.19. Following the earnings report the stock price went down -1.786%.
Which hedge fund is a major shareholder of Elevation Oncology?
Among the largest hedge funds holding Elevation Oncology’s share is Farallon Capital Management, L.L.C.. It holds Elevation Oncology’s shares valued at 2M.
---
Elevation Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (981.17% Upside)
$6.50 (981.17% Upside)
Blogger Sentiment
Bullish
ELEV Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.72%
12-Months-Change
Fundamentals
Return on Equity
-63.67%
Trailing 12-Months
Asset Growth
6.33%
Trailing 12-Months
Company Description
Elevation Oncology
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
---
ELEV Stock 12 Month Forecast
Average Price Target
$6.50
▲(981.17% Upside)
Technical Analysis
Best Analysts Covering ELEV
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-4.69%
reiterated a buy rating 7 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -4.69% per trade.
---